IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2026. Highlights and Outlook Q1 sales grew 16.7% to $1.65 billion1, constant currency2 sales grew 12.7% Q1 TAVR sales grew 14.4% to $1.20 billion1; constant currency2 sales grew 11.0% Q1 TMTT sales of $173 million1,3, driven by repair and replacement therapies Q1 EPS of $0.661; adjusted2 EPS of $0.781 Raising FY 2026 constant currency2 sales growth guidance to 9% to
Other News
Anaxiom Announces Early Clinical Results from First-in-Human Experience of Novel Minimally Invasive Obesity Device; Advances Toward U.S. Early Feasibility Study
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Anaxiom Corporation, a clinical-stage medical device company developing a novel, non-surgical treatment for obesity, today announced the successful completion of a 12-patient OUS clinical study. Early results demonstrate device safety and promising weight loss supporting advancement toward a U.S. Early Feasibility Study. Promising Early Clinical Experience The […]
NEW STUDY LINKS GLP-1 MEDICATIONS TO LOWER RISK OF ATRIAL FIBRILLATION, INDEPENDENT OF WEIGHT LOSS
CHICAGO, IL, APRIL 23, 2026 – A new study analyzing data from more than 13,000 patients found that people using the increasingly popular weight-loss drugs known as GLP-1 receptor agonists (GLP-1-RAs) have a reduced risk of atrial fibrillation (AF), even after accounting for the medications’ effects on weight loss and overall […]
Late-Breaking Data from PRESERVE Trial Evaluates XVIVO’s HOPE Preservation Approach in Heart Transplantation
Preliminary results suggest potential to support extended preservation time and donor heart utilization TORONTO–(BUSINESS WIRE)–XVIVO, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified […]
APPLE WATCH CAPTURES MORE PEDIATRIC ARRHYTHMIA EVENTS THAN TRADITIONAL PATCH MONITORS
CHICAGO, IL, APRIL 25, 2026 – A new study examining the accuracy of wearable technologies for capturing irregular heartbeats in children found that the Apple Watchâ can capture arrhythmia events potentially more effectively than traditional ambulatory patch rhythm monitors. Researchers presented these findings as an oral abstract today at Heart Rhythm 2026. Arrhythmias occur […]
FLEX Vascular Announces 12-Month Real-World Outcomes Demonstrating Strong Safety, Durability, and Reduced Reinterventions with FLEX™ Vessel Prep System
LONDON, April 23, 2026 /PRNewswire/ — Minneapolis-based FLEX Vascular announced the presentation of 12-month results from the FLEX FIRST AV Registry, a prospective, multi-center, real-world study evaluating the FLEX™ Vessel Prep System in patients with dysfunctional hemodialysis access….
NorthStar Mapping System Now Commercially Available in the United States
MINNEAPOLIS–(BUSINESS WIRE)– #WeareiMR–Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce the U.S. commercial launch of its NorthStar® Mapping System. As the first and only cardiac mapping and guidance system designed specifically to harness the power of magnetic resonance (MR) imaging to see the heart throughout a minimally-invasive interventional procedure, NorthStar brings the field of interventional MR (iMR) to life. NorthStar provides physicians with an entirely ne
HOPPR Expands Medical Imaging AI Portfolio with Chest Radiography Narrative Model
New vision-language model translates chest X-rays into descriptive, structured text, giving developers a foundation for radiology workflow applications. The HOPPR™ MC Chest Radiography Narrative Model is a Vision Language Model that translates chest X-rays into structured narrative text…
Viz.ai Announces Strategic Collaboration to Expand Access to AI-Powered Subdural Hemorrhage Care
SAN FRANCISCO–(BUSINESS WIRE)– #ai–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic commercialization collaboration with Johnson & Johnson to expand access to Viz.ai’s Subdural Hemorrhage software solution across hospitals in the United States for automated detection, labeling and quantification of subdural collections. By integrating the Viz Subdural solution into its neurovascular offerings, the company aims to support hospital
Philips launches new Bridge Plus Occlusion Balloon to help manage rare but life-threatening SVC tears during lead extraction
Clinical illustration of the Philips Bridge Plus balloon in use
Clinical illustration of the Philips Bridge Plus balloon in use
The Philips Bridge Plus Balloon, uninflated prior to use
The Philips Bridge Plus Balloon, uninflated prior to use
The inflated Philips Bridge Plus Balloon
The inflated Philips Bridge Plus Balloon
April 23, 2026 Bridge Plus was designed for rare, life-threatening emergencies to help control bleeding during superior vena cava (SVC) tears, which occur in



